Although there are already a few existing compounds for use in the treatment of bone diseases, these new compounds may have efficacy exceeding that of current commercial species. In some cases, existing treatments have high toxicity and low efficacy. These new compounds may, therefore, be better than existing therapeutic options.
These new compounds can help restore the natural balance between normal bone destruction and replacement. They are also potential candidates for the treatment of cancer and infectious diseases as related compounds have been shown to kill tumor cells and parasites. They have been shown to stimulate T-Cells, assisting in the treatment of cancer and infectious diseases.
They have multiple targets, some involved in regulating apoptosis, and displays increased potency, making it a possible cancer drug. Its improved cell availability lowers the effective dose and can lead to fewer side effects.
These compounds make up a series of bisphosphonates useful for the treatment of bone-related diseases, cancer and infections caused by protozoa and bacteria. The compounds represent new compositions of matter. Current clinical Bisphosphonates contain a nitrogen atom that can be positively charged. The new compounds have positively charged P, As, Sb, S, Se or Te sites instead of nitrogen. They may have higher activity in treating a variety of diseases than existing compounds and may have lower toxicity than existing compounds.
- Treatment of bone diseases, cancer and infections
- Increased potency, makes it a possible cancer therapeutic
- Improved cellular availability lowers the effective dose required and can lead to fewer side effects
- Potential higher activity in treating a variety of diseases than existing compounds
- May have lower toxicity than existing compounds